ArticleTheranostics2018
Tumor-targeted hybrid protein oxygen carrier to simultaneously enhance hypoxia-dampened chemotherapy and photodynamic therapy at a single dose.
Open access · goldAbstract read
In one paragraph
Article in Theranostics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
6.2field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 116 citations in OpenAlex.
- Photodynamic therapy in head and neck squamous cell carcinoma: immunomodulation and stromal targeting of cancer-associated fibroblasts.Translational oncology · 2026Review
- Nano-orchestrated magnetotactic-like navigation for electromagnetic theranostics and immune enhancement via photoautotrophic oxygenation, mild hyperthermia, and ferroptosis.Journal of nanobiotechnology · 2025Article
- A Hybrid Protein-Oxygen Nanomedicine Overcomes Osimertinib Resistance in NSCLC via HIF-1α/VEGF/EGFR Inhibition.International journal of nanomedicine · 2025Article
- Targeting tumor angiogenesis and metabolism with photodynamic nanomedicine.Frontiers in cell and developmental biology · 2025Review
- Locally Injectable Chitosan/β-Glycerophosphate Hydrogel Doped with Triptolide-Human Serum Albumin Nanoparticles for Treating Rheumatoid Arthritis.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Article
- Photonic control of image-guided ferroptosis cancer nanomedicine.Coordination chemistry reviews · 2024Article
- The application of peroxidase mimetic nanozymes in cancer diagnosis and therapy.Frontiers in pharmacology · 2024Review
- Recent Advances of Tumor Microenvironment-Responsive Nanomedicines-Energized Combined Phototherapy of Cancers.Pharmaceutics · 2023Review
- Bladder microenvironment actuated proteomotors with ammonia amplification for enhanced cancer treatment.Acta pharmaceutica Sinica. B · 2023Article
- Multifunctional Protein Hybrid Nanoplatform for Synergetic Photodynamic-Chemotherapy of Malignant Carcinoma by Homologous Targeting Combined with Oxygen Transport.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Low-temperature plasma-activated medium enhances the chemosensitivity of colorectal cancer cells by improving hypoxia.American journal of cancer research · 2023Article
- Cell Membrane Coated pH-Responsive Intelligent Bionic Delivery Nanoplatform for Active Targeting in Photothermal Therapy.International journal of nanomedicine · 2023Article
- Innovative strategies for photodynamic therapy against hypoxic tumor.Asian journal of pharmaceutical sciences · 2023Review
- Porous SiOInternational journal of nanomedicine · 2023Article
- Spotlight on Photoactivatable Liposomes beyond Drug Delivery: An Enabler of Multitargeting of Molecular Pathways.Bioconjugate chemistry · 2022Review
- Synergic Antitumor Effect of Photodynamic Therapy and Chemotherapy Mediated by Nano Drug Delivery Systems.Pharmaceutics · 2022Review
- Developing Smart Nanoparticles Responsive to the Tumor Micro-Environment for Enhanced Synergism of Thermo-Chemotherapy With PA/MR Bimodal Imaging.Frontiers in bioengineering and biotechnology · 2022Article
- Recent Progress of Metal-Organic Framework-Based Photodynamic Therapy for Cancer Treatment.International journal of nanomedicine · 2022Review
- Tumor pH-Responsive Nanocarriers With Light-Activatable Drug Release for Chemo-Photodynamic Therapy of Breast Cancer.Frontiers in chemistry · 2022Article
Corrections and comments
- Commented on by
Authors and funding
10 authors at 3 institutions in 1 country.
Zhenyu LuoGuangdong Key Laboratory of Nanomedicine, Shenzhen engineering Laboratory of nanomedicine and nanoformulations, CAS Key Lab for Health Informatics, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, P. R. China.
Hao TianGuangdong Key Laboratory of Nanomedicine, Shenzhen engineering Laboratory of nanomedicine and nanoformulations, CAS Key Lab for Health Informatics, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, P. R. China.
Lanlan LiuGuangdong Key Laboratory of Nanomedicine, Shenzhen engineering Laboratory of nanomedicine and nanoformulations, CAS Key Lab for Health Informatics, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, P. R. China.
Zhikuan ChenGuangdong Key Laboratory of Nanomedicine, Shenzhen engineering Laboratory of nanomedicine and nanoformulations, CAS Key Lab for Health Informatics, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, P. R. China.
Ruijing LiangGuangdong Key Laboratory of Nanomedicine, Shenzhen engineering Laboratory of nanomedicine and nanoformulations, CAS Key Lab for Health Informatics, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, P. R. China.
Ze ChenGuangdong Key Laboratory of Nanomedicine, Shenzhen engineering Laboratory of nanomedicine and nanoformulations, CAS Key Lab for Health Informatics, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, P. R. China.
Zhihao WuGuangdong Key Laboratory of Nanomedicine, Shenzhen engineering Laboratory of nanomedicine and nanoformulations, CAS Key Lab for Health Informatics, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, P. R. China.
Aiqing MaGuangdong Key Laboratory of Nanomedicine, Shenzhen engineering Laboratory of nanomedicine and nanoformulations, CAS Key Lab for Health Informatics, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, P. R. China.
Mingbin ZhengGuangdong Key Laboratory of Nanomedicine, Shenzhen engineering Laboratory of nanomedicine and nanoformulations, CAS Key Lab for Health Informatics, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, P. R. China.
Lintao CaiGuangdong Key Laboratory of Nanomedicine, Shenzhen engineering Laboratory of nanomedicine and nanoformulations, CAS Key Lab for Health Informatics, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, P. R. China.
Shenzhen Institutes of Advanced Technology · CNUniversity of Chinese Academy of Sciences · CNGuangdong Medical College · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypoxia is a characteristic feature of solid tumors and an important causation of resistance to chemotherapy and photodynamic therapy (PDT). It is challenging to develop efficient functional nanomaterials for tumor oxygenation and therapeutic applications.
Indexed as
AnimalsAntineoplastic AgentsCarrier ProteinsCell Line, TumorChlorophyllidesDisease Models, AnimalDoxorubicinDrug TherapyHemoglobinsHumansMice, Inbred BALB CMice, NudeModels, BiologicalNanomedicineNeoplasmsOxygenAntineoplastic AgentsCarrier ProteinsChlorophyllidesDoxorubicinHemoglobinsOxygenphytochlorinPorphyrinsRadiation-Sensitizing Agentschemotherapyhybrid protein nanoparticlephotodynamic therapytargeted oxygen carriertumor hypoxia
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.